KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Cash from Discontinued Operations (2020 - 2022)

Pfizer (PFE) has disclosed Cash from Discontinued Operations for 9 consecutive years, with 5000000.0 as the latest value for Q3 2022.

  • On a quarterly basis, Cash from Discontinued Operations fell 129.41% to 5000000.0 in Q3 2022 year-over-year; TTM through Oct 2022 was 332000000.0, a 115.84% decrease, with the full-year FY2021 number at 343000000.0, down 108.88% from a year prior.
  • Cash from Discontinued Operations was 5000000.0 for Q3 2022 at Pfizer, up from 327000000.0 in the prior quarter.
  • In the past five years, Cash from Discontinued Operations ranged from a high of 2414000000.0 in Q3 2020 to a low of 327000000.0 in Q4 2021.
  • A 3-year average of 564428571.43 and a median of 17000000.0 in 2021 define the central range for Cash from Discontinued Operations.
  • Peak YoY movement for Cash from Discontinued Operations: tumbled 98.07% in 2021, then plummeted 129.41% in 2022.
  • Pfizer's Cash from Discontinued Operations stood at 2414000000.0 in 2020, then tumbled by 113.55% to 327000000.0 in 2021, then surged by 98.47% to 5000000.0 in 2022.
  • Per Business Quant, the three most recent readings for PFE's Cash from Discontinued Operations are 5000000.0 (Q3 2022), 327000000.0 (Q4 2021), and 17000000.0 (Q3 2021).